Connection
Christopher Wardell to Cell Line, Tumor
This is a "connection" page, showing publications Christopher Wardell has written about Cell Line, Tumor.
|
|
Connection Strength |
|
|
|
|
|
0.110 |
|
|
|
-
Smiech M, Leszczynski P, Wardell C, Poznanski P, Pierzchala M, Taniguchi H. Oncogenic Mutation BRAF V600E Changes Phenotypic Behavior of THLE-2 Liver Cells through Alteration of Gene Expression. Int J Mol Sci. 2022 Jan 28; 23(3).
Score: 0.037
-
Fok JHL, Hedayat S, Zhang L, Aronson LI, Mirabella F, Pawlyn C, Bright MD, Wardell CP, Keats JJ, De Billy E, Rye CS, Chessum NEA, Jones K, Morgan GJ, Eccles SA, Workman P, Davies FE. HSF1 Is Essential for Myeloma Cell Survival and A Promising Therapeutic Target. Clin Cancer Res. 2018 05 15; 24(10):2395-2407.
Score: 0.028
-
Bright MD, Itzhak DN, Wardell CP, Morgan GJ, Davies FE. Cleavage of BLOC1S1 mRNA by IRE1 Is Sequence Specific, Temporally Separate from XBP1 Splicing, and Dispensable for Cell Viability under Acute Endoplasmic Reticulum Stress. Mol Cell Biol. 2015 Jun; 35(12):2186-202.
Score: 0.023
-
B?gsted M, Bilgrau AE, Wardell CP, Bertsch U, Schmitz A, B?dker JS, Kjeldsen MK, Goldschmidt H, Morgan GJ, Dybkaer K, Johnsen HE. Proof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myeloma. PLoS One. 2013; 8(12):e83252.
Score: 0.021
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|